Guselkumab in patients with moderately to severely active ulcerative colitis (QUASAR): phase 3 double-blind, randomised, placebo-controlled induction and maintenance studies
David T. Rubin(University of California System), Patrick Chamouard, Jozef Baláž, Antonio Blanco, Monika Augustyn, Shadi Yarandi(Janssen (United States)), Hale Akpınar, П. С. Андреев, Julián Panés(Hospital Clínic de Barcelona), Fabrizio Bossa(Istituti di Ricovero e Cura a Carattere Scientifico), Axel Dignaß(Goethe University Frankfurt), Laurent Peyrin‐Biroulet(Délégation Centre-Est), Jakob Begun, Brian G. Feagan(Western University), Toshifumi Ashida, Alessandro Armuzzi, Rebbecca Wilson(Janssen (United States)), Lore Billiauws(Université Paris Cité), Brian Bressler(University of British Columbia), Jessica R. Allegretti(Brigham and Women's Hospital), Houssam Al Kharrat, Federico Ariel, Jewel Johanns(Janssen (United States)), Elena Bunkova, Niazy Abu-farsakh, Flavio Caprioli(University of Rome Tor Vergata), Domingo Balderramo(Hospital Privado), Martin Bortlík, Guy Aumais, Qian Cao, Engin Altıntaş, Romain Altwegg(Université de Montpellier), Nicole Shipitofsky(Janssen (United States)), Halyna Afanasieva, Kuan‐Hsiang Gary Huang(Janssen (United States)), Rute Cerqueira(Icahn School of Medicine at Mount Sinai), Marjorie Argollo(Universidade Federal de São Paulo), Mercedes Cabello(Hospital Regional Universitario de Málaga), Bruce E Sands(Icahn School of Medicine at Mount Sinai), Filip Baert(AZ Delta), О. Аbrahamovych, Kazuki Aomatsu, Gary R. Lichtenstein(University of Pennsylvania), Tadakazu Hisamatsu(Kyorin University), Hongyan Zhang(Northwest A&F University), Martín Azum, Matthew Germinaro(Johnson & Johnson (United States)), Temenuzhka Berova, Karen A. Chachu(Washington University in St. Louis)
Cited by 95
Related Papers
Infliximab for Induction and Maintenance Therapy for Ulcerative Colitis
|New England Journal of Medicine|2005|3.9k
Vedolizumab as Induction and Maintenance Therapy for Ulcerative Colitis
|New England Journal of Medicine|2013|2.9k
Vedolizumab as Induction and Maintenance Therapy for Crohn's Disease
|New England Journal of Medicine|2013|2.7k